A	O
role	O
for	O
the	O
locus	B:C0023951
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	O
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	B:C0948482
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	O
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	B:C0067685
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	O
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	B:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	O
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	B:C0014432
ZJ43	O
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	B:C1451894
and	O
2	O
-	I:C0910831
PMPA	I:C0910831
.	O

A	O
role	O
for	O
the	O
locus	O
coeruleus	I:C0023951
in	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
N	O
-	I:C0067685
acetylaspartylglutamate	I:C0067685
peptidase	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
inhibitors	O
ZJ43	O
and	O
2	B:C0910831
-	I:C0910831
PMPA	I:C0910831
.	O

N-	B:C0130693
acetylaspartylglutamate	I:C0130693
(	O
N-	O
acetylaspartylglutamate	I:C0130693
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	O
in	O
the	O
mammalian	O
nervous	O
system	I:C0027763
.	O

N-	O
acetylaspartylglutamate	I:C0130693
(	O
N-	B:C0130693
acetylaspartylglutamate	I:C0130693
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	O
in	O
the	O
mammalian	O
nervous	O
system	I:C0027763
.	O

N-	O
acetylaspartylglutamate	I:C0130693
(	O
N-	O
acetylaspartylglutamate	I:C0130693
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B:C0027908
in	O
the	O
mammalian	O
nervous	O
system	I:C0027763
.	O

N-	O
acetylaspartylglutamate	I:C0130693
(	O
N-	O
acetylaspartylglutamate	I:C0130693
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	O
in	O
the	O
mammalian	B:C0024660
nervous	O
system	I:C0027763
.	O

N-	O
acetylaspartylglutamate	I:C0130693
(	O
N-	O
acetylaspartylglutamate	I:C0130693
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	O
in	O
the	O
mammalian	O
nervous	B:C0027763
system	I:C0027763
.	O

N-	B:C0130693
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	O
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	O
vivo	I:C1515655
.	O

N-	O
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	B:C0532371
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	O
vivo	I:C1515655
.	O

N-	O
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	O
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	B:C0532371
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	O
vivo	I:C1515655
.	O

N-	O
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	O
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	B:C0067685
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	O
vivo	I:C1515655
.	O

N-	O
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	O
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	B:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	O
vivo	I:C1515655
.	O

N-	O
acetylaspartylglutamate	I:C0130693
activates	O
a	O
group	O
II	I:C0532371
metabotropic	I:C0532371
glutamate	I:C0532371
receptor	I:C0532371
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	I:C0067685
,	I:C0067685
glutamate	I:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
(	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
)	O
in	B:C1515655
vivo	I:C1515655
.	O

Inhibitors	B:C0014432
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	O
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	O
and	O
bone	O
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	B:C0002771
in	O
animal	O
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	O
and	O
bone	O
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	B:C0599779
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	O
and	O
bone	O
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	O
models	I:C0599779
of	O
inflammatory	B:C0234251
,	O
neuropathic	O
and	O
bone	O
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	O
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	B:C3714625
and	O
bone	O
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	O
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	O
and	O
bone	B:C0279530
cancer	I:C0279530
pain	O
.	O

Inhibitors	O
of	I:C0014432
this	I:C0014432
enzyme	I:C0014432
are	O
analgesic	O
in	O
animal	O
models	I:C0599779
of	O
inflammatory	O
,	O
neuropathic	O
and	O
bone	O
cancer	I:C0279530
pain	B:C0030193
.	O

N-	B:C0130693
acetylaspartylglutamate	I:C0130693
and	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
are	O
present	O
in	O
the	O
locus	O
coeruleus	I:C0023951
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	O
inhibitory	O
pain	O
system	O
.	O

N-	O
acetylaspartylglutamate	I:C0130693
and	O
glutamate	B:C0067685
carboxypeptidase	I:C0067685
II	I:C0067685
are	O
present	O
in	O
the	O
locus	O
coeruleus	I:C0023951
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	O
inhibitory	O
pain	O
system	O
.	O

N-	O
acetylaspartylglutamate	I:C0130693
and	O
glutamate	O
carboxypeptidase	I:C0067685
II	I:C0067685
are	O
present	O
in	O
the	O
locus	B:C0023951
coeruleus	I:C0023951
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	O
inhibitory	O
pain	O
system	O
.	O

In	O
the	O
formalin	B:C0949307
footpad	O
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	B:C2985236
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	O
model	B:C0012644
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	O
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	B:C0014432
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	O
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B:C0234251
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	O
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	B:C0521329
noradrenaline	O
.	O

In	O
the	O
formalin	O
footpad	O
model	O
,	O
systemic	O
treatment	O
with	O
GCPII	O
inhibitors	I:C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	B:C0028351
.	O

This	O
analgesic	B:C0948482
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	B:C0021485
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	B:C0532371
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	B:C1254351
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	B:C0021896
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	B:C0304513
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	B:C0025991
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	B:C1254351
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	B:C0441988
locus	O
coeruleus	I:C0023951
.	O

This	O
analgesic	O
efficacy	I:C0948482
is	O
blocked	O
by	O
systemic	O
injection	O
of	O
a	O
group	O
II	I:C0532371
mGluR	I:C0532371
antagonist	O
,	O
by	O
intrathecal	O
(	I:C0021896
spinal	I:C0021896
)	I:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
and	O
by	O
microinjection	O
of	O
an	O
α	O
-	I:C1254351
amino	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
hydroxy	I:C1254351
-	I:C1254351
5	I:C1254351
-	I:C1254351
methylisoxazole	I:C1254351
-	I:C1254351
4-	I:C1254351
propionic	I:C1254351
acid	I:C1254351
(	I:C1254351
AMPA	I:C1254351
)	I:C1254351
receptor	I:C1254351
antagonist	I:C1254351
directly	O
into	O
the	O
contralateral	O
locus	B:C0023951
coeruleus	I:C0023951
.	O

Footpad	B:C2985236
inflammation	O
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	O
locus	O
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	O
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Footpad	O
inflammation	B:C0021368
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	O
locus	O
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	O
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Footpad	O
inflammation	O
increases	O
release	O
of	O
glutamate	B:C0017789
in	O
the	O
contralateral	O
locus	O
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	O
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Footpad	O
inflammation	O
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	B:C0441988
locus	O
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	O
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Footpad	O
inflammation	O
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	O
locus	B:C0023951
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	O
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Footpad	O
inflammation	O
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	O
locus	O
coeruleu	I:C0023951
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	B:C0014432
inhibitor	I:C0014432
blocks	O
this	O
increase	O
.	O

Direct	O
injection	B:C0021485
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	B:C0014432
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	B:C0441988
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	B:C0441989
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	B:C0023951
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B:C0234251
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	B:C0441988
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	B:C0021896
injection	I:C0021896
of	O
an	O
alpha	O
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

Direct	O
injection	O
of	O
GCPII	O
inhibitors	I:C0014432
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	O
coeruleus	I:C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	O
pain	I:C0234251
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	O
injection	I:C0021896
of	O
an	O
alpha	B:C0304513
2	I:C0304513
adrenergic	I:C0304513
receptor	I:C0304513
antagonist	I:C0304513
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	B:C0948482
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	O
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	B:C0014432
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	O
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	B:C0441988
l	O
locus	O
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	B:C0023951
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	O
coeruleus	I:C0023951
via	O
group	B:C0532371
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	O
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	B:C1528634
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	O
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	O
efficacy	I:C0948482
of	O
systemically	O
administered	O
GCPII	O
inhibitors	I:C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	O
coeruleus	I:C0023951
via	O
group	O
II	I:C0532371
mGluR	I:C0532371
,	O
α-	O
amino	I:C1528634
-	I:C1528634
3	I:C1528634
-	I:C1528634
hydroxy	I:C1528634
-	I:C1528634
5	I:C1528634
-	I:C1528634
methylisoxazole	I:C1528634
-	I:C1528634
4-	I:C1528634
propionic	I:C1528634
acid	I:C1528634
and	O
alpha	B:C0001639
2	I:C0001639
adrenergic	I:C0001639
receptors	I:C0001639
.	O

